We are pleased to share with you a new report from Deloitte Access Economics: The New Wave of Immunotherapy Cancer Medicines: The Untapped Potential for Australians.
The report, sponsored by MSD, explores the rise of immunotherapies in cancer treatment and the potential of these medicines in the fight against cancer, while also providing an account of the patient experience, including specific barriers to awareness of and access to these immunotherapies.
Importantly, the report reveals that thousands of Australians who face imminent death from cancer could live longer if new medicines that harness the immune system to fight cancer cells became more readily accessible.
The report notes that reimbursement delays and capacity constraints remain barriers to access in Australia, taking 597 days on average for a cancer medicine to be listed on the PBS – 200 days longer than other disease areas.
Additionally, the report calls for medicine approval and reimbursement systems in Australia to be overhauled to expedite access to immunotherapies; including adopting a tumour agnostic approach similar to that recently approved by the FDA.
To view the full report, click here